Antibody Drug Conjugates Industry Drive CAGR of 10.91% By 2032

Published Date : 02 May 2023

In 2022, the size of the antibody drug conjugates industry accounted for USD 9.04 billion and is projected to expand at the fastest compound annual growth rate (CAGR) of 10.91% between 2023 and 2032, resulting in an estimated industry size of USD 25.46 billion by 2032.

Highly efficient biotech drugs known as antibody-drug conjugates are used as tailored therapies for the treatment of cancer. ADCs are made to only destroy cancer cells, protecting healthy cells from damage. This is a significant benefit of ADCs because the undamaged healthy cells help patients recuperate more quickly.

Market Growth:

One of the antitumor medications with the quickest growth is antibody-drug conjugates (ADC). This method uses a mAb attached to a cytotoxic cargo via a chemical linker that is aimed at a target protein expressed on the surface of the cancer cell, minimizing systemic exposure and toxicity. ADCs are intricate compounds that need special consideration for several factors. ADCs' safety and effectiveness are largely determined by the choice of a suitable target, a mAb, a cytotoxic payload, and how the antibody is attached to the payload.

Even though the creation of successful cancer therapies using antibody-drug conjugates appears promising, several difficulties still exist in ensuring the secure production of these dangerous medications. The biopharmaceutical business continues to see growth in the use of antibody-drug conjugates (ADCs), which are anti-cancer medications that combine the specificity of a monoclonal antibody with the cell-killing effectiveness of a highly powerful active pharmaceutical component (HPAPI). More businesses are seeking to create these medicines as early results from these targeted treatments' studies demonstrate their efficacy.

Antibody Drug Conjugates Industry Report Scope:

Report Coverage Details
Market Size in 2022 USD 9.04 Billion
Projected Forecast Revenue in 2032 USD 25.46 Billion
Growth Rate from 2023 to 2032 CAGR of 10.91%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Regional Analysis:

Due to growing cancer rates and technological advancements, North America is anticipated to experience substantial growth during the forecast time. Due to countries in the region, like the United States, Canada, and Mexico, making major technological strides, the area is expanding significantly. High rates of malignancy are prevalent in North American nations. The industry is expanding in the area due to the rising incidence of cancer cases. For instance, the American Cancer Society predicted that in 2022, 1.9 million new instances of cancer would be discovered in the country.

The second-largest industry for antibody-drug conjugates worldwide is found in europe. In the United Kingdom, cancer accounts for over 25% of annual fatalities, and the disease is becoming more common in other European nations, which is boosting the industry's expansion there.

The Asia Pacific antibody drug conjugates industry is expected to expand as a result of the rising cancer incidence and aging populace in the area. Researchers have also been compelled to create improved cancer therapy choices as a result of the increasing rates of gastric, ovarian, and lung cancer in China and India.

Market Dynamics:


Future ADC advancements will incorporate fresh or recycled technological fields

Future ADC developments will include novel or repurposed areas of technology, which may require additional investments from CMOs active in the area and could benefit from their technical expertise. While the technologies created by Seattle Genetics and Immunogen are now well-established and understood, they will also include new or modified areas of technology.

The use of even more powerful HPAPI payloads in ADCs is becoming more common, so confinement and decontamination skills will need to be improved to deal with this. Non-monoclonal antibody targeting regions are also of relevance. Whether these are bispecific antibodies, fragment antigen-binding antibodies, or something entirely new, production procedures must be revised to meet the new specifications. To satisfy the manufacturing requirements for future ADC products, process skills will need to be improved as drug formulation advances.


Higher production cost

The cost of raw materials, the use of technology, the lengthy production process, and the demand for a trained and professional workforce control the cost of production for antibody-drug conjugates. Additionally, changes in the cost of basic resources have an impact on manufacturing expenses. Companies in the biotechnology and pharmaceutical industries spend a lot of money on R&D.


Enhancing the private sector's contribution to the fight against cancer

ADCs are being developed by a large number of biopharma businesses, including both Big Pharma and tiny biotech firms. The promise of ADCs for other therapeutic areas, such as autoimmune illnesses, or the use of conjugates to develop new diagnostics, is, however, also the subject of considerable study.

Acute myeloid leukemia was first treated with Mylotarg, a first-generation ADC medication from Wyeth (now Pfizer), in 2000. Although it was discontinued ten years later due to safety issues and the fact that there were more effective chemotherapy alternatives available, it established the idea that such medicines offer potential in the treatment of cancer.

Application Insights:

The largest industry share for worldwide antibody-drug conjugates comes from the breast cancer sector. One of the most important developments in the treatment of metastatic breast cancer has been the creation of anti-HER2 drugs, which have greatly increased mortality rates. Anti-HER2 monoclonal antibodies are effective, but concomitant treatment is still necessary to optimize the reaction. The family of medicines known as antibody-drug conjugates (ADCs) pairs an antigen-specific antibody backbone with a powerful cytotoxic payload to increase the therapeutic index.

During the forecast period, the blood cancer industry sector is anticipated to hold a sizable stake. Blood cancer, which affects blood cells and is the fifth most prevalent variety of cancer, comes in many different forms. Leukemia and cancer rates have risen recently, too, during the same period.

Technology Insights:

The industry proportion for antibody-drug conjugates worldwide that the cleavable linker technology sector commands are the largest. As it can discharge cytotoxin from the antibody-drug conjugates, the cleavable linker technology is the most widely used technique in antibody-drug conjugate treatment. By employing the natural characteristics of tumor cells, cleavable linkers contribute significantly to the success of antibody-drug conjugates; their unrivaled benefits in the therapy of cancer further support the segment's expansion.

Recent Development:

  • In February 2023, Lantern Pharma, a clinical-stage pharmaceutical business, recently revealed updates and extensions to RADR, its main platform, to speed up and lower the cost of oncology drug research. The growth seeks to quicken the pace of new findings in the field of developing Cancer/Oncology Drugs.
  • In February 2023, to emphasize the choice of new targets for antibody-drug conjugates and T-cell redirection modalities, Immunome, a clinical-stage biotechnology firm that develops novel targeted antibody pairs, has revealed the establishment of an advisory group.
  • In February 2023, Exelixis and Sairopa of the Netherlands reported that the FDA had approved Sairpoa's Investigational New Drug (IND) Application to assess the safety of ADU-1805 in individuals with solid tumors. A possible best-in-class polyclonal antibody is Sairopa's ADU-1805. The approval, in Sairopa's opinion, has established a foundation for future developments in cancer therapy.
  • In February 2023, Innovative biotechnology firm Hillstream BioPharma recently disclosed that the business had entered into an exclusive option agreement with Applied Biomedical Science Institute (ABSI) to license the technology for HER2 and HER3 in human monoclonal antibodies to develop multi-format biologics and antibody drug conjugates for the treatment of gastric, ovarian, and breast cancer.

Major Key Players:

  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • AstraZeneca
  • Seagen Inc
  • ADC Therapeutics
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd

Market Segmentation:

By Application

  • Blood Cancer
  • Breast Cancer
  • Urothelial Cancer
  • Bladder Cancer

By Technology

  • Cleavable
  • Non-cleavable

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333